Trusted Partner

The Difference is in the Data

MMS is the data-focused CRO driving pharmaceutical and biotech innovation with unparalleled regulatory expertise and technological innovation. Our experts across four continents are available to support your programs 24 hours a day with an industry-leading Sponsor satisfaction rating.

Full Service Biometrics

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

Regulatory Submissions

From the Investigational New Drug (IND) application stage through New Drug Applications (NDA), our deep expertise ensures that your drug development process is efficient, compliant, and strategically aligned with standards set by global health authorities.

Safety & Risk Management

Comprehensive pharmacovigilance, safety and risk management from Phase 1 through post approval, tailored to your specific needs.

Therapeutic Expertise

From industry-firsts to well-researched indications, MMS brings specialized knowledge in rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others.

Functional Service Provider (FSP)

A flexible and scalable FSP model, providing the right level of oversight, scale, and governance to achieve your long- and short-term strategic goals.

What Differentiates MMS From Other CROs?

Responsive

MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.

Adaptable

MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.

Focused

MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.

Sponsor feedback
This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.
SVP, Global Regulatory Affairs
Sponsor feedback
The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models.
Dr. Steven Gullans, CEO
Sponsor feedback
I cannot thank the MMS Team for the outstanding support you’re providing to ensure these are prepared for submission. I am continuously impressed with the MMS team and truly value the partnership.
Global Pharma Sponsor

AI and Technology

Sponsors can rest assured knowing that MMS will bring new levels of innovation and technology to our processes and deliverables.

2006
MMS Founded
in Michigan
950
Loyal
Colleagues
Globally
50
Marketing
Applications in the
Last 5 Years
1
CRO you can
trust

Upcoming Events

MMS Insights

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer

perspectives

August 13th, 2024

How To Navigate The Nonclinical Evaluation Landscape Of Biopharmaceuticals

perspectives

August 5th, 2024

Ensuring Robust Data Privacy and Protection: An Overview of the MMS Framework